• In May 2026, ImmunityBio announced that the FDA accepted for review its supplemental Biologics License Application to expand ANKTIVA plus BCG to BCG-unresponsive non-muscle invasive bladder cancer with papillary disease, supported by QUILT-3.032 data showing chemo-free, bladder-sparing outcomes.
• An interesting element of this filing is the FDA’s emphasis on whether ANKTIVA’s existing CIS data can be extrapolated to papillary-only disease, putting the drug’s mechanistic rationale and trial design under close scientific scrutiny.
• We’ll now examine how the FDA’s sBLA review for expanding ANKTIVA’s papillary NMIBC indication could influence ImmunityBio’s broader investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you need to believe ANKTIVA can anchor a durable bladder cancer franchise while management broadens into new indications before cash constraints bite. The FDA’s sBLA review for papillary-only NMIBC is now a central near term catalyst, but the agency’s focus on extrapolating CIS data and its reservations about single arm evidence also sharpens the main risk: tighter regulatory standards that could slow new label expansions and keep revenue concentrated.

The May 2026 sBLA acceptance for papillary NMIBC ties directly into ImmunityBio’s broader bladder strategy, especially alongside its new exclusive U.S. development and supply agreement for Tokyo-172 BCG. If Tokyo BCG ultimately secures approval, it could sit alongside ANKTIVA in addressing BCG-unresponsive disease and chronic BCG shortages, potentially reinforcing, but not de risking, the papillary sBLA as a key approval and revenue inflection point.

Yet while the upside is appealing, investors should also pay close attention to how the FDA’s scrutiny of single arm data and extrapolation could affect ANKTIVA’s future labels...

ImmunityBio's narrative projects $1.2 billion revenue and $435.5 million earnings by 2029. This requires 118.9% yearly revenue growth and about a $787 million earnings increase from -$351.4 million today.

Uncover how ImmunityBio's forecasts yield a $13.50 fair value, a 75% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming ANKTIVA could drive revenue to about US$1.6 billion and earnings near US$672 million by 2029, which is far more bullish than views that focus on trial and regulatory setbacks around BCG naive bladder cancer potentially constraining the BioShield platform, so this latest sBLA review may ultimately shift how you weigh these very different stories about ImmunityBio’s future.

Explore 9 other fair value estimates on ImmunityBio - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ImmunityBio research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.